|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM309707420 |
| 003 |
DE-627 |
| 005 |
20250227062705.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108457
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1032.xml
|
| 035 |
|
|
|a (DE-627)NLM309707420
|
| 035 |
|
|
|a (NLM)32387537
|
| 035 |
|
|
|a (PII)S1521-6616(19)30718-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ishibashi, Fumihiro
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.01.2021
|
| 500 |
|
|
|a Date Revised 29.01.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a UMIN-CTR: UMIN000005208
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We conducted a phase I study of the trans-bronchial injection of α-galactosylceramide (αGalCer)-pulsed antigen presenting cells (APCs) to evaluate their safety, immune responses, and anti-tumor activities. Patients with advanced or recurrent non-small cell lung cancer (NSCLC) refractory to standard treatments were eligible. αGalCer-pulsed APCs were administered intratumorally or intranodally by bronchoscopy. Twenty-one patients were enrolled in this study. No severe adverse events related to the cell therapy were observed during this study in any patient. After αGalCer-pulsed APCs were administrated, increased iNKT cell numbers were observed in PBMCs from eight cases, and IFN-γ producing cells were increased in the peripheral blood of 10 cases. Regarding clinical responses, one case exhibited a partial response and eight were classified as stable disease. In the tumor microenvironment, IFN-γ expression was upregulated after treatment in partial response or stable disease cases and TGF-β was upregulated in progressive disease cases
|
| 650 |
|
4 |
|a Clinical Trial, Phase I
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Antigen presenting cells
|
| 650 |
|
4 |
|a Bronchoscopy
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
4 |
|a Lung cancer
|
| 650 |
|
4 |
|a NKT cells
|
| 650 |
|
7 |
|a Galactosylceramides
|2 NLM
|
| 650 |
|
7 |
|a alpha-galactosylceramide
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Sakairi, Yuichi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Iwata, Takekazu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moriya, Yasumitsu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mizobuchi, Teruaki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hoshino, Hidehisa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yoshida, Shigetoshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hanaoka, Hideki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yoshino, Ichiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Motohashi, Shinichiro
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 215(2020) vom: 01. Juni, Seite 108457
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:215
|g year:2020
|g day:01
|g month:06
|g pages:108457
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108457
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 215
|j 2020
|b 01
|c 06
|h 108457
|